In one paragraphTrial report in Circulation. Arrhythmia and electrophysiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
21 authors.
Zachary T YonedaDepartment of Medicine, Division of Cardiovascular Medicine (Z.T.Y., D.M.C., M.A.E.-H., J.M., S.T.S., J.C.E., P.J.S., C.R.E., T.R., A.K., G.H.C., M.B.S.), Vanderbilt University Medical Center, Nashville, TN.ORCID 0000-0002-2055-732X Matthew O'NeillVanderbilt University School of Medicine, Nashville, TN (M.O.N.).
Diane M CrawfordDepartment of Medicine, Division of Cardiovascular Medicine (Z.T.Y., D.M.C., M.A.E.-H., J.M., S.T.S., J.C.E., P.J.S., C.R.E., T.R., A.K., G.H.C., M.B.S.), Vanderbilt University Medical Center, Nashville, TN.ORCID 0000-0002-6160-2828 Mingfang AoDepartment of Pharmacology (M.A.), Vanderbilt University Medical Center, Nashville, TN.
Lili SunDepartment of Biostatistics (L.S., F.Y.), Vanderbilt University Medical Center, Nashville, TN.ORCID 0000-0002-5112-6389 Majd A El-HarasisDepartment of Medicine, Division of Cardiovascular Medicine (Z.T.Y., D.M.C., M.A.E.-H., J.M., S.T.S., J.C.E., P.J.S., C.R.E., T.R., A.K., G.H.C., M.B.S.), Vanderbilt University Medical Center, Nashville, TN.
Jay MontgomeryDepartment of Medicine, Division of Cardiovascular Medicine (Z.T.Y., D.M.C., M.A.E.-H., J.M., S.T.S., J.C.E., P.J.S., C.R.E., T.R., A.K., G.H.C., M.B.S.), Vanderbilt University Medical Center, Nashville, TN.ORCID 0000-0002-9950-940X Sharon T ShenDepartment of Medicine, Division of Cardiovascular Medicine (Z.T.Y., D.M.C., M.A.E.-H., J.M., S.T.S., J.C.E., P.J.S., C.R.E., T.R., A.K., G.H.C., M.B.S.), Vanderbilt University Medical Center, Nashville, TN.ORCID 0000-0002-7959-300X Juan Carlos EstradaDepartment of Medicine, Division of Cardiovascular Medicine (Z.T.Y., D.M.C., M.A.E.-H., J.M., S.T.S., J.C.E., P.J.S., C.R.E., T.R., A.K., G.H.C., M.B.S.), Vanderbilt University Medical Center, Nashville, TN.ORCID 0000-0003-0209-1850 Pablo J SaavedraDepartment of Medicine, Division of Cardiovascular Medicine (Z.T.Y., D.M.C., M.A.E.-H., J.M., S.T.S., J.C.E., P.J.S., C.R.E., T.R., A.K., G.H.C., M.B.S.), Vanderbilt University Medical Center, Nashville, TN.ORCID 0000-0003-2665-5112 Christopher R EllisDepartment of Medicine, Division of Cardiovascular Medicine (Z.T.Y., D.M.C., M.A.E.-H., J.M., S.T.S., J.C.E., P.J.S., C.R.E., T.R., A.K., G.H.C., M.B.S.), Vanderbilt University Medical Center, Nashville, TN.ORCID 0000-0002-7333-5720 Travis RichardsonDepartment of Medicine, Division of Cardiovascular Medicine (Z.T.Y., D.M.C., M.A.E.-H., J.M., S.T.S., J.C.E., P.J.S., C.R.E., T.R., A.K., G.H.C., M.B.S.), Vanderbilt University Medical Center, Nashville, TN.ORCID 0000-0002-9772-0308 Arvindh KangasundramDepartment of Medicine, Division of Cardiovascular Medicine (Z.T.Y., D.M.C., M.A.E.-H., J.M., S.T.S., J.C.E., P.J.S., C.R.E., T.R., A.K., G.H.C., M.B.S.), Vanderbilt University Medical Center, Nashville, TN.ORCID 0000-0001-8295-1528 George H CrossleyDepartment of Medicine, Division of Cardiovascular Medicine (Z.T.Y., D.M.C., M.A.E.-H., J.M., S.T.S., J.C.E., P.J.S., C.R.E., T.R., A.K., G.H.C., M.B.S.), Vanderbilt University Medical Center, Nashville, TN.ORCID 0000-0003-0096-8401 Fei YeDepartment of Biostatistics (L.S., F.Y.), Vanderbilt University Medical Center, Nashville, TN.ORCID 0000-0001-6472-5076 Dan M RodenDepartments of Medicine, Pharmacology, and Biomedical Informatics, Divisions of Cardiovascular Medicine and Clinical Pharmacology (D.M.R.), Vanderbilt University Medical Center, Nashville, TN.ORCID 0000-0002-6302-0389 M Benjamin Shoemaker *Department of Medicine, Division of Cardiovascular Medicine (Z.T.Y., D.M.C., M.A.E.-H., J.M., S.T.S., J.C.E., P.J.S., C.R.E., T.R., A.K., G.H.C., M.B.S.), Vanderbilt University Medical Center, Nashville, TN.ORCID 0000-0001-6824-7155 Funding
Vanderbilt Institute for Clinical and Translational Research (VICTR) -Identifying correlates of functional immunity in SARS-CoV-2 convalescent plasmaUL1TR002243 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Paul A. Harris, Wesley H Self · 2017 to 2026
$130.7MAmerican Heart Association-American Stroke Association 18SFRN34110369NCATS NIH HHS UL1 TR002243
6 · The paper itselfAbstract
backgroundInflammation is a common mechanism for atrial fibrillation (AF). 2-Hydroxybenzylamine (2-HOBA) is a novel therapeutic that scavenges isolevuglandins-a downstream mediator of inflammation and oxidative stress. 2-HOBA is safe and reduces AF in mice, prompting a first-in-human pilot clinical trial.
methodsParticipants were enrolled and randomized 1:1 to placebo or 2-HOBA (750 mg p.o. TID) 3 days before a planned AF ablation. Participants were monitored for 28 days after their ablation for recurrence of AF as detected by smartwatch single-lead ECG recordings. Blood was collected at the time of ablation for measurement of isolevuglandin levels. The study drug was stopped at 28 days. A 12-month extended follow-up period was used to monitor for any residual effect of the study drug on AF recurrence.
results2-HOBA increased the risk of AF recurrence in the postablation population (odds ratio, 3.65 [95% CI, 1.31-10.16];
conclusions2-HOBA was associated with a higher risk of AF recurrence when tested early after AF ablation. This result was unexpected based on preclinical data, but paradoxical associations with AF have been previously reported for other drugs that target inflammation and oxidative stress pathways, such as omega-3 fatty acids. The mechanisms for AF immediately following ablation may be different from AF that occurs under other conditions, and the generalizability of these results to all forms of AF remains unknown.
Indexed as
Anti-Arrhythmia AgentsAtrial FibrillationBenzylaminesCatheter AblationHeart RateAgedDouble-Blind MethodFemaleHumansMaleMiddle AgedPilot ProjectsRecurrenceTime FactorsTreatment OutcomeAnti-Arrhythmia AgentsBenzylaminesatrial fibrillationhumansinflammationoxidative stressrisk factors
Identifiers
PMID40709466
PMCPMC12812325
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390